EAA232
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
- NCT06948084 ↗
- Recruiting
- National Cancer Institute (NCI)
- Focused
We haven't built an HCP commentary report on EAA232 (daratumumab and recombinant human hyaluronidase, teclistamab and 3 more in Recurrent Multiple Myeloma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on EAA232 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 7 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase II Trial for High-Risk Multiple Myeloma That is Refractory or in First Relapse With Daratumumab, Teclistamab (DT) Versus Daratumumab, Pomalidomide, Dexamethasone (DPd) or Daratumumab, Carfilzomib, Dexamethasone (DKd)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Recurrent Multiple Myeloma; Refractory Multiple Myeloma
- Interventions
- Biospecimen Collection; Bone Marrow Biopsy; Carfilzomib; Computed Tomography; Daratumumab and Recombinant Human Hyaluronidase; Dexamethasone; FDG-Positron Emission Tomography; Pomalidomide; Teclistamab
- Arms
- Arm A Treatment I (DPd) · Active comparator
- Arm A Treatment II Option 1 (DKd) · Active comparator
- Arm A Treatment II Option 2 (DKd) · Active comparator
- Arm B (daratumumab, teclistamab) · Experimental
- Enrollment
- 80 (estimated)
- Primary outcomes
- Minimal residual disease (MRD) negativity
- Sponsor
- National Cancer Institute (NCI)
- Start
- May 22, 2027 (estimated)
- Primary completion
- Feb 28, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06948084 · updated Oct 28, 2026